{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:27:41Z","timestamp":1791876461665,"version":"4.3.4"},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Department of Health & Family Welfare, Govt. of Kerala, India","award":["2210-05-200-91"],"award-info":[{"award-number":["2210-05-200-91"]}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research, New Delhi","doi-asserted-by":"crossref","award":["2019-4701 & 2019-4739"],"award-info":[{"award-number":["2019-4701 & 2019-4739"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Kessler et al. in this current issue have attempted to discern biomarker(s) for spinal muscular atrophy (SMA) by assessing alterations in cerebrospinal fluid (CSF) proteomics profile. Recently, antisense oligonucleotide (nusinersen) therapy is shown to mitigate pathologies and provide behavioral improvements in patients. This Editorial highlights the study by Kessler et al on the proteomics of CSF from adult and young patients prior to, and 10\u00a0months after nusinersen intrathecal therapy. Although the study by Kessler et al. suffers from small sample size and mixed results that deterred a strong conclusion, yet is a strong case\u2012control study that is contemporary and important to the patients, clinicians and care\u2010takers alike. Since identifying biomarker and characterizing the pathology in SMA are imminent necessity to advance this promising therapy, the high\u2010throughput CSF proteomics data prior and after nusinersen therapy provide possible biomarkers that may help in identification of positive responders, the disease course, efficacy of treatment, and more accurate prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:label\/><jats:p>\n<jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/jnc14976-fig-0002-m.png\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:boxed-text>\n<\/jats:p><\/jats:sec>","DOI":"10.1111\/jnc.14976","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T05:56:45Z","timestamp":1583301405000},"page":"545-548","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The light at the end of the tunnel gets vivid for spinal muscular atrophy"],"prefix":"10.1111","volume":"153","author":[{"given":"Debashis","family":"Dutta","sequence":"first","affiliation":[{"name":"Department of Neurological Sciences Rush University Medical Center Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goutam","family":"Chandra","sequence":"additional","affiliation":[{"name":"Inter University Centre for Biomedical Research &amp; Super Speciality Hospital Mahatma Gandhi University Campus at Thalappady Kottayam Kerala India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4985-1100","authenticated-orcid":false,"given":"Kochupurackal P.","family":"Mohanakumar","sequence":"additional","affiliation":[{"name":"Inter University Centre for Biomedical Research &amp; Super Speciality Hospital Mahatma Gandhi University Campus at Thalappady Kottayam Kerala India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010716-104846"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.779"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13945"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00735"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.14953"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60921-6"},{"key":"e_1_2_6_8_1","first-page":"e14935","article-title":"Combined treatment with the histone deacetylase inhibitor LBH589 and a splice\u2010switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells","volume":"6","author":"Pagliarini V.","year":"2019","journal-title":"Journal of Neurochemistry"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(02)00332-0"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508947102"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418803246"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1800260115"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419846058"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01179"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418776932"},{"key":"e_1_2_6_16_1","article-title":"Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen","author":"Wurster C. D.","year":"2019","journal-title":"Journal of Neurology"}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjnc.14976","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jnc.14976","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jnc.14976","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jnc.14976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T13:57:59Z","timestamp":1694008679000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jnc.14976"}},"subtitle":["An Editorial Highlight for \u201cCerebrospinal fluid proteomic profiling in nusinersen\u2010treated patients with spinal muscular atrophy\u201d on page 650."],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1111\/jnc.14976"],"URL":"https:\/\/doi.org\/10.1111\/jnc.14976","archive":["Portico"],"relation":{},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"value":"0022-3042","type":"print"},{"value":"1471-4159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"assertion":[{"value":"2020-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}